- Home
- SCYX vs VTGN Comparison
SCYX vs VTGN Comparison
Compare SCYX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCYX | VTGN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 28.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCYX | VTGN |
|---|---|---|
| Price | $0.67 | $0.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $3.00 | $0.90 |
| AVG Volume (30 Days) | 408.0K | ★ 6.2M |
| Earning Date | 11-05-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,932,000.00 | $721,000.00 |
| Revenue This Year | $167.73 | $54.26 |
| Revenue Next Year | $290.78 | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $0.63 |
| 52 Week High | $1.31 | $5.14 |
Technical Indicators
Market Signals| Indicator | SCYX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 24.05 |
| Support Level | $0.58 | $0.63 |
| Resistance Level | $0.64 | $0.77 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 91.33 | 17.96 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.